Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
TAG Mail 2 December 2015 The purpose of TAG Mail is to assist TAG members identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAG Mail to others who they believe would benefit from this information such as colleagues in the same hospital department if they are not already receiving TAG Mail. TAG ACTIVITIES **Meetings - TAG General Meeting – 14 December 2015 - 3.00pm – St Vincent’s Hospital or via teleconference - TAGNet Meeting – 15 December2015 - 11.00am - TAG Offices or via teleconference **Sasha Bennett and Margaret Jordan attended the APSA-ASCEPT Joint Scientific Meeting in Hobart 29 Nov – 2 Dec 2015. NSW TAG had three presentations accepted: “Hospital evaluation of medicine usage………past its DUE date?” (Poster) “An analysis of prescribing and supply of medicines for ophthalmic surgery in NSW hospitals” (Poster) “Optimising the logistics of life-saving drug procurement and supply in NSW and the ACT” (Oral presentation) **Sasha Bennett, Andrew Hargreaves, Margaret Jordan and Christa Lynch will be attending Medicines Management 2015, the 41st SHPA National Conference in Melbourne 3-6 December 2015. Andrew Hargreaves will present: “Mining Diamonds: Crystalising Safety & Quality standards for eHealth NSW’s flagship eMeds Program” (Poster) **Email discussions: - IV phenytoin administration and use of filters; closes 3 December 2015 TAG WEBSITE - Report: An analysis of prescribing and supply of medicines for ophthalmic surgery in NSW public hospitals – 2015 http://www.ciap.health.nsw.gov.au/nswtag/pages/project-reports.html - Email discussion: ToujeoTM Insulin 300units/mL (members only) http://www.ciap.health.nsw.gov.au/nswtag/pages/email-discussions.html REPORTS AND PUBLICATIONS – AUSTRALIA **AIHW - The health of Australia’s prisoners 2015 http://www.aihw.gov.au/publication-detail/?id=60129553527 - Australia’s registered health professions workforce http://www.aihw.gov.au/workforce-data/ **ACSHC - Australian Atlas of Healthcare Variation http://www.safetyandquality.gov.au/atlas/ **TGA - Updates to the list of designated orphan drugs: Alectinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Sebelipase Alfa for the treatment of lysosomal acid lipase (LAL) deficiency https://www.tga.gov.au/updates-list-designated-orphan-drugs - AusPAR added : Apremilast (OtezlaR) approved for the treatment of signs and symptoms of active psoriatic arthritis in adult patients, and the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. http://www.tga.gov.au/auspar/auspar-apremilast - AusPAR added: Regorafenib (StivargaR) extension of indication approved, for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. https://www.tga.gov.au/auspar/auspar-regorafenib-0 - AusPAR added: Certolizumab pegol (Cimzia R) extension of indication. Approved for rheumatoid arthritis “Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when given in combination with MTX.” https://www.tga.gov.au/auspar/auspar-certolizumab-pegol-rbe - AusPAR added : Apixaban (Eliquis) extension of indication. Approved for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients and for the prevention of recurrent DVT and PE in adult patients. https://www.tga.gov.au/auspar/auspar-apixaban-1 - AusPAR added: Anakinra (Kineret) extension of indication. Approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA). Anakinra may be used alone or in combination with DMARDs’. https://www.tga.gov.au/auspar/auspar-anakinra - AusPAR added: Rifaximin (Xifaxan) extension of indication. Approved for the treatment of adult patients with travellers’ diarrhoea caused by non-invasive enteric bacteria. https://www.tga.gov.au/auspar/auspar-rifaximin-0 **NPS Medicinewise - Atlas shines a light on healthcare variation http://www.nps.org.au/media-centre/media-releases/repository/atlas-shines-a-light-on-healthcare-variation - Medicinal cannabis: the evidence and the challenges http://www.nps.org.au/media-centre/media-releases/repository/medicinal-cannabis-theevidence-and-thechallenges - National Medicines Symposium 2016 http://www.nps.org.au/about-us/what-we-do/campaigns-events/national-medicines-symposium/nms-2016making-wise-decisions-about-medicines-tests-and-technologies - NPS Direct - November 2015 http://www.nps.org.au/health-professionals/e-newsletters/nps-direct/2015/november - NPS RADAR December 2015 http://www.nps.org.au/publications/health-professional/nps-radar/2015/december-2015 REPORTS AND PUBLICATIONS – INTERNATIONAL **CADTH - Treatment of Angiotensin Converting Enzyme Inhibitor-Induced Angioedema: Guidelines https://www.cadth.ca/sites/default/files/pdf/htis/nov2015/RB0938%20Icatibant%20for%20Angioedema%20Fi nal.pdf - Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines https://www.cadth.ca/sites/default/files/pdf/htis/nov2015/RC0720%20Bismuth%20Subsalicylate%20Final.pdf **FDA - Necitumumab (PortrazzaR) approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (in combination with two forms of chemotherapy) who have not previously received medication specifically for treating their advanced lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474131.htm - FDA approves FluadR, the first seasonal influenza vaccine containing an adjuvant. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm - Elotuzumab (EmplicitiR) approved to treat patients with multiple myeloma (in combination with two other therapies) who have received one to three prior medications. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm **EMA - Risk minimisation strategy for high-strength and fixed-combination insulin products http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/ WC500196980.pdf - Good practice guide on recording, coding, reporting and assessment of medication errors http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/ WC500196979.pdf - Good practice guide on risk minimisation and prevention of medication errors http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/ WC500196981.pdf **NICE -- Guidance - Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset http://www.nice.org.uk/guidance/ng16 - Transition between inpatient hospital settings and community or care home settings for adults with social care needs http://www.nice.org.uk/guidance/ng27 MEDICATION SAFETY **TGA - Medicines Safety update volume 6 number 6 December 2015 https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-6-number-6-december-2015 **GOV.UK - Drug Safety Update – November 2015 https://www.gov.uk/government/publications/drug-safety-update-monthly-newsletter PAPERS OF INTEREST **Australian Journal of Primary Health - Medication-taking behaviour in New South Wales patients with type 2 diabetes: an observational study http://www.publish.csiro.au/nid/261/paper/PY14062.htm **British Journal of Clinical Pharmacology - Proton Pump Inhibitor Associated Hypomagnasaemia - A Cause for Concern? http://onlinelibrary.wiley.com/doi/10.1111/bcp.12846/abstract - Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer http://onlinelibrary.wiley.com/doi/10.1111/bcp.12790/abstract - Evidence for the changing regimens of acetylcysteine http://onlinelibrary.wiley.com/doi/10.1111/bcp.12789/full **BMJ - Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials http://www.bmj.com/content/351/bmj.h5203 **EJHP - Optimal dosing of angiotensin-converting enzyme inhibitors and β-blockers for acute coronary syndrome: uptitration remains a challenge http://ejhp.bmj.com/content/early/2015/11/27/ejhpharm-2015-000783.short?g=w_ejhp_ahead_tab **JAMA Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial http://jama.jamanetwork.com/article.aspx?articleid=2473492 **JAMIA The impact of real-time alerting on appropriate prescribing in kidney disease: a cluster randomized controlled trial http://jamia.oxfordjournals.org/content/early/2015/11/27/jamia.ocv159 **Journal of Clinical Oncology - Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial http://jco.ascopubs.org/content/33/34/3999.abstract **Journal for healthcare quality Medication Discrepancies During Transitions of Care: A Comparison Study http://journals.lww.com/jhqonline/Abstract/2015/11000/Medication_Discrepancies_During_Transitions_of.1. aspx **Clinics in Geriatric Medicine Long-term Toxicity of Cancer Treatment in Older Patients http://www.sciencedirect.com/science/article/pii/S0749069015000737 CONSULTATIONS **TGA - Proposed amendments to the poisons standard: Closes 10 December 2015 https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acmsmeeting-march-2016 OTHER NEWS Nil UPCOMING EVENTS (new additions in bold) **Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug Monitoring) and JSS University, Asia Pacific Pharmacovigilance Training Course, 18-29 January, 2016, Mysore, India http://jsspharma.org/sites/default/files/downloads/Asia_Pacific_Pharmacovigilance.pdf **EAHP 21st Congress of the EAHP (European Association of Hospital Pharmacists) ‘Hospital pharmacists taking the lead – partnerships and technologies’, 16-18 March 2016, Vienna, Austria http://www.eahp.eu/congresses **International Association of Risk Management in Medicine “IARMM General Assembly 2016” jointly with "5th World Congress of Clinical Safety (5WCCS)", 21 - 23 September 2016, Harvard University Medical School Boston, USA http://www.iarmm.org/5WCCS/(poster)5WCCS_2016.pdf **EUFEPS - European Federation for Pharmaceutical Sciences 2016 Meeting “Clinical Outcome and Regulatory Approaches for Advanced Drug Delivery Products”, 13-15 June 2016, Istanbul Turkey www.eufepsannualmeeting.org **IHI - Breakthrough Series College, March 29–31, 2016 , Cambridge, MA, USA http://www.ihi.org/education/InPersonTraining/BreakthroughSeriesCollege/March2016BTSCollege/Pages/def ault.aspx?utm_campaign=BTSC+March+2016&utm_source=hs_email&utm_medium=email&utm_content=232 97166&_hsenc=p2ANqtz-8OZ9FlsGQcddH1o-ZNv6O1HroyFhMRkGGNJGguLz6tVMFNzzDnfEnD27lS_AvTGX8l9wNb0ItEXMdDxKH86r4Nb2f1A&_hsmi=23297166 - Patient Safety Executive Development Program March 3-9, 2016 Cambridge, MA http://www.ihi.org/education/InPersonTraining/PatientSafetyExecutive/PatientSafetyExecutiveDevelopment March2016/Pages/default.aspx?utm_campaign=2016+March+PSO&utm_source=hs_email&utm_medium=em ail&utm_content=23544167&_hsenc=p2ANqtz-93OUZyfrSpkxcCiEMBnZJ1H7xK3GHpQESS91qc89pkN1_5QGSKD6EGuewKQ4lmkVym2oaQKK029gb3_Gu-RRumC9EWw&_hsmi=23544167 **The Laboratory of Innovative Practices on Polypharmacy and Health 3rd International Short Film and Photography Festival, May 2016 The participants' short films and photos should cover one of the following issues: - Primary health care understood as the essential health care accessible to all individuals and families in the community by means acceptable to them, with their full participation and at an affordable cost to the community. -Safe, appropriate and prudent use of medicines understood as the absence of unnecessary actual or potential harm associated with medicines use. -Medicalization of life understood as the process by which events of everyday life are converted into health problems; and from that perspective they are addressed and treated by different health professionals. Entries close 30 April 2016 http://polimedicado.org You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at [email protected] if you have any questions regarding this.